DP2: Decision on continued trading restriction on UPCoM and Notice on stock status

Following Decision No. 265/QD-SGDHN dated April 01, 2025, HNX announces the continued trading restriction of DP2 stock as follows:
- Reason for trading restriction: the audit organization have expressed disclaimer opinion on the Annual Financial Statement 2024;
- Ground for continued trading restriction: The audited Financial Statement of 2024;
- Trading restriction: be traded on Friday weekly;
- Applicable law(s): Points c, Section 1 Article 34 of the Regulations attached to Decision No.34/QD-HDTV dated 16/11/2022 of the Vietnam Exchange.
Within 15 days from the date the stock is under continued trading restriction as prescribed in this Decision, Central Pharmaceutical Joint Stock Company No2 must send a document to the HNX to explain the cause and provide a remedy.
--------------------------------------------------------------------------------------------------------------------------------------------
On April 01, 2025, HNX announces the status of Central Pharmaceutical Joint Stock Company No2’s shares (stock code: DP2) as follows: DP2 share are under continued trading restriction due to the reason(s) that the audit organization have expressed disclaimer opinion on the Annual Financial Statements 2024 as prescribed at points c, Section 1, Article 34 of the Regulations attached to Decision No.34/QD-HDTV dated 16/11/2022 of the Vietnam Exchange.